251 related articles for article (PubMed ID: 19066131)
1. Hereditary breast/ovarian cancer: clinicopathological characteristics and survival of BRCA2 positive and negative cases.
Syamala V; Syamala VS; Sreeja L; Raveendran PB; Vijayalekshmi RV; Sheeja VR; Santhi S; Kuttan R; Abraham EK; Ankathil R
J Exp Ther Oncol; 2008; 7(3):227-36. PubMed ID: 19066131
[TBL] [Abstract][Full Text] [Related]
2. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
3. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
[TBL] [Abstract][Full Text] [Related]
4. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
Machado PM; Brandão RD; Cavaco BM; Eugénio J; Bento S; Nave M; Rodrigues P; Fernandes A; Vaz F
J Clin Oncol; 2007 May; 25(15):2027-34. PubMed ID: 17513806
[TBL] [Abstract][Full Text] [Related]
5. Germline BRCA1 mutation and survival analysis in familial breast cancer patients in Kerala; South India.
Vinodkumar B; Syamala V; Abraham EK; Balakrishnan R; Ankathil R
J Exp Clin Cancer Res; 2007 Sep; 26(3):329-36. PubMed ID: 17987791
[TBL] [Abstract][Full Text] [Related]
6. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
[TBL] [Abstract][Full Text] [Related]
7. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
[TBL] [Abstract][Full Text] [Related]
8. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.
Kwiatkowska E; Teresiak M; Filas V; Karczewska A; Breborowicz D; Mackiewicz A
Clin Cancer Res; 2003 Oct; 9(12):4452-9. PubMed ID: 14555518
[TBL] [Abstract][Full Text] [Related]
9. Screening for RAD51 and BRCA2 BRC repeat mutations in breast and ovarian cancer families.
Rapakko K; Heikkinen K; Karppinen SM; Winqvist R
Cancer Lett; 2006 May; 236(1):142-7. PubMed ID: 16005565
[TBL] [Abstract][Full Text] [Related]
10. A BRCA2 mutation, 4088insA, in a Finnish breast and ovarian cancer family associated with favourable clinical course.
Hartikainen JM; Mannermaa A; Heinonen S; Kosma VM; Kataja V
Anticancer Res; 2007; 27(6C):4295-300. PubMed ID: 18214034
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients.
Verhoog LC; Berns EM; Brekelmans CT; Seynaeve C; Meijers-Heijboer EJ; Klijn JG
J Clin Oncol; 2000 Nov; 18(21 Suppl):119S-24S. PubMed ID: 11060339
[TBL] [Abstract][Full Text] [Related]
12. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
Brekelmans CT; Tilanus-Linthorst MM; Seynaeve C; vd Ouweland A; Menke-Pluymers MB; Bartels CC; Kriege M; van Geel AN; Burger CW; Eggermont AM; Meijers-Heijboer H; Klijn JG
Eur J Cancer; 2007 Mar; 43(5):867-76. PubMed ID: 17307353
[TBL] [Abstract][Full Text] [Related]
13. Effect of germ-line genetic variation on breast cancer survival in a population-based study.
Goode EL; Dunning AM; Kuschel B; Healey CS; Day NE; Ponder BA; Easton DF; Pharoah PP
Cancer Res; 2002 Jun; 62(11):3052-7. PubMed ID: 12036913
[TBL] [Abstract][Full Text] [Related]
14. [Clinical analysis of 91 cases of hereditary breast and ovarian cancer].
Li N; Wu LY; Zhang R; Zhang X; Liu LY
Zhonghua Zhong Liu Za Zhi; 2005 Apr; 27(4):245-7. PubMed ID: 15949430
[TBL] [Abstract][Full Text] [Related]
15. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.
Brozek I; Ochman K; Debniak J; Morzuch L; Ratajska M; Stepnowska M; Stukan M; Emerich J; Limon J
Gynecol Oncol; 2008 Feb; 108(2):433-7. PubMed ID: 17997147
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
[TBL] [Abstract][Full Text] [Related]
17. Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases.
Veronesi A; de Giacomi C; Magri MD; Lombardi D; Zanetti M; Scuderi C; Dolcetti R; Viel A; Crivellari D; Bidoli E; Boiocchi M
BMC Cancer; 2005 Jul; 5():70. PubMed ID: 15996267
[TBL] [Abstract][Full Text] [Related]
18. A novel BRCA1 mutation in an Indian family with hereditary breast/ovarian cancer.
Gajalakshmi P; Natarajan TG; Selvi Rani D; Thangaraj K
Breast Cancer Res Treat; 2007 Jan; 101(1):3-6. PubMed ID: 17131039
[TBL] [Abstract][Full Text] [Related]
19. Four primary malignancies successively occurred in a BRCA2 mutation carrier: a case report.
Fruscalzo A; Damante G; Calcagno A; Di Loreto C; Marchesoni D
Cancer Invest; 2006 Oct; 24(6):611-4. PubMed ID: 16982466
[TBL] [Abstract][Full Text] [Related]
20. BRCA2 alteration is important in clear cell carcinoma of the ovary.
Goodheart MJ; Rose SL; Hattermann-Zogg M; Smith BJ; De Young BR; Buller RE
Clin Genet; 2009 Aug; 76(2):161-7. PubMed ID: 19656163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
